Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 22903769)

1.

Pneumococcal polysaccharide vaccine efficacy and routine use of conjugate vaccines in infants: there is no need for a vaccine program in older adults at present.

Trück J, Lazarus R, Jonsdottir I, Klugman KP, Pollard AJ.

Clin Infect Dis. 2012 Dec;55(11):1577-9; author reply 1579-81. doi: 10.1093/cid/cis700. Epub 2012 Aug 17. No abstract available.

2.

Vaccine Update: Recommendation for conjugate pneumococcal and pneumococcal polysaccharide vaccines in adults older than 65 years.

Niemi SA, Foster SL, Hayney MS.

J Am Pharm Assoc (2003). 2015 Mar-Apr;55(2):212, 214-5. doi: 10.1331/JAPhA.2015.15511. No abstract available.

PMID:
25749266
3.

Use of pneumococcal vaccine in adults.

Pisano J, Cifu AS.

JAMA. 2015 Feb 17;313(7):719-20. doi: 10.1001/jama.2015.63. No abstract available.

PMID:
25688784
4.

PCV13 in the USA: early successes and potential challenges.

Stockmann C, Byington CL.

Lancet Infect Dis. 2015 Mar;15(3):254-6. doi: 10.1016/S1473-3099(15)70018-6. Epub 2015 Feb 3. No abstract available.

PMID:
25656599
5.

Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older.

Menzies RI, Krause VL, McIntyre PB.

Med J Aust. 2014 Aug 18;201(4):200. No abstract available.

PMID:
25164842
6.

Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older.

Collignon PJ.

Med J Aust. 2014 Aug 18;201(4):199-200. No abstract available.

PMID:
25164841
7.

[The risk of pneumococcal diseases in lung diseases and the importance of adult vaccination].

Sayıner A, Mirici A, Çilli A, Uzaslan E, Akova M, Özhan MH, Kilinç O.

Tuberk Toraks. 2014;62(2):154-9. Turkish. No abstract available.

8.

Further evidence for the effectiveness of PCV10 against Streptococcus pneumoniae serotype 19A.

Clarke CJ, Hausdorff WP.

Lancet Respir Med. 2014 Jun;2(6):e7. doi: 10.1016/S2213-2600(14)70128-6. No abstract available.

PMID:
24899371
9.

Prevention of invasive pneumococcal disease: new evidence.

Rodgers G.

Lancet Respir Med. 2014 Jun;2(6):432-4. doi: 10.1016/S2213-2600(14)70076-1. Epub 2014 Apr 10. No abstract available.

PMID:
24726405
10.

Should the indication of pneumococcal polysaccharide vaccine in children be definitively withdrawn?

Martinón-Torres F.

Clin Infect Dis. 2014 Jul 1;59(1):138. doi: 10.1093/cid/ciu228. Epub 2014 Apr 9. No abstract available.

11.

Pneumococcal vaccines WHO position paper--2012.

[No authors listed]

Wkly Epidemiol Rec. 2012 Apr 6;87(14):129-44. English, French. No abstract available.

PMID:
24340399
12.

Measurement of pneumococcal polysaccharide antibodies.

Sorensen RU, Leiva LE.

J Clin Immunol. 2014 Feb;34(2):127-8. doi: 10.1007/s10875-013-9977-z. Epub 2013 Dec 17. No abstract available.

PMID:
24337649
13.

The challenge of preventing invasive pneumococcal disease in children with comorbid illnesses.

Pelton SI.

Clin Infect Dis. 2014 Feb;58(4):526-7. doi: 10.1093/cid/cit792. Epub 2013 Dec 2. No abstract available.

14.

Distribution of pneumococcal serotypes in adult pneumococcal pneumonia cases: filling the evidence gap to inform vaccination policies.

Griffin MR, Grijalva CG.

J Infect Dis. 2013 Dec 1;208(11):1734-6. doi: 10.1093/infdis/jit510. Epub 2013 Oct 2. No abstract available.

15.

Pneumococcal disease in New Zealand and prevailing inequalities, the tip of the lower respiratory infection iceberg.

Petousis-Harris HA.

N Z Med J. 2013 Jul 12;126(1378):9-11. No abstract available.

PMID:
24045310
16.

Colonisation endpoints in Streptococcus pneumoniae vaccine trials.

Auranen K, Rinta-Kokko H, Goldblatt D, Nohynek H, O'Brien KL, Satzke C, Simell B, Tanskanen A, Käyhty H; Pneumococcal Carriage Group (PneumoCarr).

Vaccine. 2013 Dec 17;32(1):153-8. doi: 10.1016/j.vaccine.2013.08.061. Epub 2013 Sep 7. Review.

PMID:
24016803
17.

Determinants of invasiveness beneath the capsule of the pneumococcus.

Klugman KP, Bentley SD, McGee L.

J Infect Dis. 2014 Feb 1;209(3):321-2. doi: 10.1093/infdis/jit483. Epub 2013 Sep 5. No abstract available.

18.

Optimizing the use of pneumococcal conjugate vaccine globally.

O'Brien KL.

JAMA. 2013 Sep 4;310(9):911-3. doi: 10.1001/jama.2013.228062. No abstract available.

PMID:
24002275
19.

The clinical and ecological impact of childhood pneumococcal vaccination.

Gil E, Noursadeghi M, Brown JS.

Br J Hosp Med (Lond). 2013 Apr;74(4):212-6. Review. No abstract available.

PMID:
23571392
20.

PCV13 impact evaluations: the obvious and the unpredicted.

O'Brien KL.

Pediatr Infect Dis J. 2013 Mar;32(3):264-5. doi: 10.1097/INF.0b013e3182787f89. No abstract available.

PMID:
23558322
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk